TTY Biopharm Company Limited

eng.tty.com.tw

TTY Biopharm Co., Ltd. was established on July 22nd 1960. TTY is a Taiwan's leading pharmaceutical manufacturing company which specializes in the development of special formulations and new drugs. TTY focuses on research & development and innovation of antitumor and against severe infection's areas. We will continue to develop in healthcare product portfolio to support the physicians and patients with completed approach to disease treatment.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

JUDGE WIPES OUT BIOGEN'S TECFIDERA PATENT PROTECTIONS IN SUIT AGAINST MYLAN

Fiercepharma | June 18, 2020

news image

In the high-stakes patent fight between Biogen and Mylan over Tecfidera’s main remaining patent, Mylan has scored a major win in federal court. U.S. District Judge Irene Keeley said Mylan “demonstrated by clear and convincing evidence” that certain claims of Biogen’s '514 patent are invalid for “lack of written description.” The decision threatens Biogen’s bestselling medicine with early generics; Tecfidera, a multiple sclerosis drug, generated $3.3 ...

Read More

Business Insights

ITERATIVE SCOPES RECEIVES FDA CLEARANCE FOR AI-ASSISTED POLYP DETECTION DEVICE SKOUT™

Iterative Scopes | September 23, 2022

news image

Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance. SKOUT, a real-time computer-aided polyp detection device developed by Iterative Scopes, uses advanced computer vision technolog...

Read More

Business Insights

CATALENT TO ACQUIRE METRICS CONTRACT SERVICES FOR $475 MILLION TO EXPAND HIGH-POTENT CAPABILITIES AND ORAL DEVELOPMENT AND MANUFACTURING CAPACITY

Catalent, Inc. | August 10, 2022

news image

Catalent, Inc. the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services a full-service specialty Contract Development and Manufacturing Organization with a facility in Greenville, North Carolina, for $475 million from Mayne Pharma Group Limited. Upon completion, the acquisition will stre...

Read More

Business Insights

STEVANATO GROUP AND GERRESHEIMER AG ANNOUNCE COLLABORATION ON THE DEVELOPMENT OF AN INNOVATIVE READY-TO-USE VIAL PLATFORM

Gerresheimer and Stevanato Group | September 08, 2022

news image

Stevanato Group S.p.A. a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Gerresheimer AG, a leading global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics, announce that they have jointly developed a high-end Ready-To-Use (RTU) solution platform with an initial focus on vials, based on Stevanato Group’s market-leading EZ-fill® technology. Th...

Read More
news image

JUDGE WIPES OUT BIOGEN'S TECFIDERA PATENT PROTECTIONS IN SUIT AGAINST MYLAN

Fiercepharma | June 18, 2020

In the high-stakes patent fight between Biogen and Mylan over Tecfidera’s main remaining patent, Mylan has scored a major win in federal court. U.S. District Judge Irene Keeley said Mylan “demonstrated by clear and convincing evidence” that certain claims of Biogen’s '514 patent are invalid for “lack of written description.” The decision threatens Biogen’s bestselling medicine with early generics; Tecfidera, a multiple sclerosis drug, generated $3.3 ...

Read More
news image

Business Insights

ITERATIVE SCOPES RECEIVES FDA CLEARANCE FOR AI-ASSISTED POLYP DETECTION DEVICE SKOUT™

Iterative Scopes | September 23, 2022

Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance. SKOUT, a real-time computer-aided polyp detection device developed by Iterative Scopes, uses advanced computer vision technolog...

Read More
news image

Business Insights

CATALENT TO ACQUIRE METRICS CONTRACT SERVICES FOR $475 MILLION TO EXPAND HIGH-POTENT CAPABILITIES AND ORAL DEVELOPMENT AND MANUFACTURING CAPACITY

Catalent, Inc. | August 10, 2022

Catalent, Inc. the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services a full-service specialty Contract Development and Manufacturing Organization with a facility in Greenville, North Carolina, for $475 million from Mayne Pharma Group Limited. Upon completion, the acquisition will stre...

Read More
news image

Business Insights

STEVANATO GROUP AND GERRESHEIMER AG ANNOUNCE COLLABORATION ON THE DEVELOPMENT OF AN INNOVATIVE READY-TO-USE VIAL PLATFORM

Gerresheimer and Stevanato Group | September 08, 2022

Stevanato Group S.p.A. a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Gerresheimer AG, a leading global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics, announce that they have jointly developed a high-end Ready-To-Use (RTU) solution platform with an initial focus on vials, based on Stevanato Group’s market-leading EZ-fill® technology. Th...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us